Drug intelligence / Profile preview

YHP1906

Development stage: Phase 1
Lead developer: Yuhan
Modality: Small Molecules
Administration: Oral

Overview

YHP1906 is a small molecule drug developed by Yuhan Corp. It is being investigated primarily for the treatment of cardiovascular and respiratory diseases, with specific indications including venous thromboembolism and pulmonary embolism. The mechanism of action and molecular targets have not been publicly disclosed as of the latest available data. Clinical development has reached Phase 1, with at least one completed bioequivalence study comparing it to another compound (YHR1902) in healthy volunteers[1][2]. No further clinical or mechanistic details are currently available.

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on YHP1906.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHP1906.

Explore the full profile